J L McClay

Summary

Affiliation: Virginia Commonwealth University
Country: USA

Publications

  1. ncbi Variance component analysis of polymorphic metabolic systems
    Joseph L McClay
    Virginia Institute for Psychiatric and Behavioral Genetics, Medical College of Virginia, Virginia Commonwealth University, Biotech 1, 800 East Leigh Street, Richmond, VA 23298 0126, USA
    J Theor Biol 240:149-59. 2006
  2. ncbi Catechol-O-methyltransferase and the clinical features of psychosis
    J L McClay
    Department of Psychiatry, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0126, USA
    Am J Med Genet B Neuropsychiatr Genet 141:935-8. 2006
  3. ncbi Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia
    Joseph L McClay
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298 0533, USA
    Neuropsychopharmacology 36:616-26. 2011
  4. ncbi Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics
    J L McClay
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA
    Mol Psychiatry 16:76-85. 2011
  5. ncbi (1)H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function
    Joseph L McClay
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, USA
    J Proteome Res 9:3083-90. 2010
  6. ncbi Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D
    D E Adkins
    Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, School of Pharmacy, Richmond, VA 23298 0581, USA
    Transl Psychiatry 2:e129. 2012
  7. ncbi Genome-wide association study of antipsychotic-induced QTc interval prolongation
    K Aberg
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    Pharmacogenomics J 12:165-72. 2012
  8. ncbi Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D
    S L Clark
    Center for Biomarker Research and Personalized Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0581, USA
    Psychol Med 42:1151-62. 2012
  9. ncbi Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
    D E Adkins
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23223, USA
    Mol Psychiatry 16:321-32. 2011
  10. ncbi Genomewide association study of movement-related adverse antipsychotic effects
    Karolina Aberg
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Biol Psychiatry 67:279-82. 2010

Detail Information

Publications13

  1. ncbi Variance component analysis of polymorphic metabolic systems
    Joseph L McClay
    Virginia Institute for Psychiatric and Behavioral Genetics, Medical College of Virginia, Virginia Commonwealth University, Biotech 1, 800 East Leigh Street, Richmond, VA 23298 0126, USA
    J Theor Biol 240:149-59. 2006
    ..We believe that implementation of this approach holds promise of a better understanding of the genotype to phenotype transition, particularly in integrating small allelic effects into larger frameworks...
  2. ncbi Catechol-O-methyltransferase and the clinical features of psychosis
    J L McClay
    Department of Psychiatry, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298 0126, USA
    Am J Med Genet B Neuropsychiatr Genet 141:935-8. 2006
    ..4). These results suggest a modest affective vulnerability conferred by this allele in psychosis, but will require replication...
  3. ncbi Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia
    Joseph L McClay
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298 0533, USA
    Neuropsychopharmacology 36:616-26. 2011
    ..This study has generated several novel candidate genes for antipsychotic response. However, our findings will require replication and functional validation. To facilitate replication efforts, we provide all GWAS p-values for download...
  4. ncbi Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics
    J L McClay
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23298, USA
    Mol Psychiatry 16:76-85. 2011
    ..This study demonstrates the potential of genome-wide association studies to discover novel genes that mediate the effects of antipsychotics, which could eventually help to tailor drug treatment to schizophrenic patients...
  5. ncbi (1)H nuclear magnetic resonance metabolomics analysis identifies novel urinary biomarkers for lung function
    Joseph L McClay
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, USA
    J Proteome Res 9:3083-90. 2010
    ..Our results will require replication and validation, but demonstrate the utility of NMR metabolomics as a screening tool for identifying novel biomarkers of pulmonary outcomes...
  6. ncbi Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D
    D E Adkins
    Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, School of Pharmacy, Richmond, VA 23298 0581, USA
    Transl Psychiatry 2:e129. 2012
    ..Although our findings require replication and functional validation, this study demonstrates the potential of GWAS to discover genes and pathways that potentially mediate adverse effects of antidepressant medications...
  7. ncbi Genome-wide association study of antipsychotic-induced QTc interval prolongation
    K Aberg
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23298, USA
    Pharmacogenomics J 12:165-72. 2012
    ..However, some genes may also be unique for drug-induced prolongation. This study demonstrates the potential of GWAS to discover genes and pathways that mediate antipsychotic-induced QT prolongation...
  8. ncbi Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D
    S L Clark
    Center for Biomarker Research and Personalized Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298 0581, USA
    Psychol Med 42:1151-62. 2012
    ..Understanding individual differences in susceptibility to antidepressant therapy side-effects is essential to optimize the treatment of depression...
  9. ncbi Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs
    D E Adkins
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, VA 23223, USA
    Mol Psychiatry 16:321-32. 2011
    ..Although our findings require replication and functional validation, this study shows the potential of GWAS to discover genes and pathways that potentially mediate adverse effects of antipsychotic medication...
  10. ncbi Genomewide association study of movement-related adverse antipsychotic effects
    Karolina Aberg
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia of Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Biol Psychiatry 67:279-82. 2010
    ..Understanding individual differences in the development of extrapyramidal side effects (EPS) as a response to antipsychotic therapy is essential to individualize treatment...
  11. ncbi Estimating the posterior probability that genome-wide association findings are true or false
    Jozsef Bukszar
    Center for Biomarker Research and Personalized Medicine, School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, 1112 East Clay Street, PO Box 980533, Richmond, Virginia 23298, USA
    Bioinformatics 25:1807-13. 2009
    ..This lack of information increases the chance of false discoveries and may result in real effects being missed...
  12. ncbi In silico whole genome association scan for murine prepulse inhibition
    Bradley Todd Webb
    Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, Richmond, VA, USA
    PLoS ONE 4:e5246. 2009
    ....
  13. ncbi High-throughput single-nucleotide polymorphism genotyping by fluorescent competitive allele-specific polymerase chain reaction (SNiPTag)
    Joseph L McClay
    SGDP Research Centre, Institute of Psychiatry, Denmark Hill, London, SE5 8AF, United Kingdom
    Anal Biochem 301:200-6. 2002
    ..We outline a number of test assays for well-characterized SNPs in human candidate genes for behavioral disorders...